BioSpace News Archive

Neurocrine Biosciences, Inc. announced interim results from the ongoing open-label KINECT®-HD2 study about INGREZZA® capsules when used for the long-term treatment of adults with chorea associated with Huntington’s disease.

Sarepta Therapeutics, Inc. today announced that senior management will participate in a fireside chat at the UBS Biopharma Conference on Thursday, Nov. 9, 2023 at 9:00 a.m. E.T.

Champions Oncology, Inc. announced its European research operations site in Bresso, Italy, received ISO-9001:2015 laboratory accreditation from the Bureau Veritas S.p.A. and ATS certification from the Lombardy Region.

Affimed N.V. announced two upcoming presentations on its lead innate cell engager AFM13 at the American Society of Hematology 2023 Annual Meeting.

Sana Biotechnology, Inc., a company focused on changing the possible for patients through engineered cells, announced that five abstracts will have poster presentations at the 65th American Society of Hematology Annual Meeting to be held December 9-12, 2023 in San Diego, CA.

Biomea Fusion, Inc. announced that abstracts related to BMF-219 and BMF-500 have been accepted for presentation at the upcoming American Society of Hematology Annual Meeting, to be held in San Diego from December 9-12, 2023.

Vetigenics announces that the first canine patient with stage 4 oral melanoma has received his first dose of Vetigenics’ fully canine anti-CTLA4 monoclonal antibody following standard of care radiation therapy.

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, announced that the Company today presented the first clinical data of povetacicept in autoimmune glomerulonephritis during a late-breaking poster session at the American Society of Nephrology (ASN) Kidney Week in Philadelphia, Pennsylvania.

Intra-Cellular Therapies, Inc. announced its financial results for the third quarter ended September 30, 2023 and provided a corporate update.

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, reported its financial results for the third quarter ended September 30, 2023, and provided an update on the Company’s operations.